ClinicalTrials.gg
Status unknownNCT03766269Updated Dec 6, 2018

Dronabinol Opioid Sparing Evaluation (DOSE) Trial

A Phase 2 interventional study of Dronabinol in Chronic Pain, sponsored by Daisy Pharma Opioid Venture, LLC. Status unknown at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-06.

Sponsored by Daisy Pharma Opioid Venture, LLC · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
280
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,283 studies in Chronic Pain with a site in United States — 258 open to participants now, 349 under way, 7 of them phase 3. Chronic Pain · United States.

Planned enrollment
138th of 1,092
280 · median 60
Started
2018
with 90 others
Phase 2
87 of 1,283
19 open now
Registered
514th of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 138th largest by planned enrollment of the 1,092 interventional ones that give a count, is one of 91 that started in 2018, is one of 87 in phase 2, and was the 514th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

258 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

253 more — sign in →

All 258 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

This study will be a 12-week, open-label trial that is designed to evaluate the Opioid-Sparing effect of Dronabinol at ranging doses when coadministered with the opioid analgesics that are currently being prescribed to patients for their chronic pain condition. The purpose of this trial will be to assess the effectiveness of Dronabinol when combined with opioid analgesics to relieve pain at lower opioid doses and to evaluate any reduction of opioid-related side effects. Participants will take the study-drug, Dronabinol, along with their regular prescribed opioids and the results will be evaluated and analyzed according to defined endpoints.

Read the detailed description

Week one of the study is a Baseline Period during which time, baseline data related to opioid dose and frequency, mood, sleep, bowel movements, and pain intensity will be collected. Participants will receive no Dronabinol during week one and will continue to take their stabilized dose of regular prescribed opioids, both baseline and rescue.

Weeks two through four is the Titration Period, during which time study participants will titrate the Dronabinol dose up to a daily dose of 20 mg of Dronabinol per day, according to a prearranged titration table. Participants will continue to take their stabilized dose of regular prescribed opioids, both baseline and rescue. Participants will be encouraged to maintain the 20mg daily total dose of Dronabinol. Participants may also reduce their dose of Dronabinol at any time (if they experience severe adverse effects) to a minimum daily dose of Dronabinol of 10mg per day. Participants who cannot tolerate at least a minimum daily dose of 10mg of Dronabinol per day will be discontinued from the study.

Weeks five through twelve is the Opioid-Sparing Period, during which time participants will be encouraged to maintain the stabilized dose of Dronabinol that they "found" during the Study-Drug Dose Finding Period. Study Participants will continue to take their regular prescribed opioids, but will be encouraged to reduce their opioid dose and/or opioid dose frequency at any time during the remainder of the study should they experience a reduction in pain and/or an improvement in opioid-related side effects.

03

Conditions studied

  • Chronic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to read, speak, and understand English;
  2. Provision of signed and dated form;
  3. Stated willingness to comply with all study procedures and availability for the duration of the study;
  4. Male, Female, or Transgender aged > 18;
  5. In fair and stable general health as evidenced by medical history and physical examination, and confirmed by prescriber;
  6. Participants who have been diagnosed with a pain condition that has not adequately responded to other treatments, in the judgement of the provider;
  7. Participants who are currently taking a stabilized dose of opioid analgesics, and who have been taking opioid analgesics for at least 3-months, and who report a score of > 3 on the Brief Pain Inventory 0-10 severity index.;
  8. Ability to take medications as prescribed and willingness to adhere to the study-drug regimen;
  9. For females of : use of highly effective for at least 1 month prior to enrollment and agreement to use such a method during study participation;
  10. Agreement to abstain from the use of cannabis or other cannabinoid compounds, other than the study-drug Dronabinol, throughout study duration;

Exclusion criteria

Exclusion Criteria:

  1. Current substance abuse by self-report;
  2. Current use of cannabis or other cannabinoid compounds;
  3. Significant baseline nausea, vomiting, sedation, or other symptoms reported by physician and or patient that may compromise the collection of study-related data;
  4. A history of seizures, head trauma, and or mental illness ;
  5. Pregnancy or lactation;
  6. Known allergic reactions to components of Dronabinol;
  7. Taking any of the following drugs:

Strong CYP2C9 Inhibitor (e.g., amiodarone, fluconazole) Strong Inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin) Potent CYP2C9 or CYP3A4 inducers (e.g., rifampicin) Drugs that are highly protein-bound (e.g., warfarin, cyclosporine, amphotericin B)

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Other
    Baseline Opioid

    One of Seven existing Baseline Opioid subgroups (Hydrocodone, Oxycodone, Morphine, Hydromorphone, Buprenorphine, Tramadol) coadministered with intervention drug, Dronabinol.

    Drug: Dronabinol

Interventions

  • Dronabinol coadministered with patient's existing Baseline Opioid.

    Also known as: Marinol

06

What researchers measure

Primary outcomes

  1. Pain Intensity Scale (0-10)

    To measure the change in pain intensity from baseline using the Opioid Sparing Diary Toolkit. The measurement of the pain intensity will be derived from the Brief Pain Inventory (Short-Form) item #3. "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the last 24 hours." The score is reported as a value between 0 and 10, with 0 indicative of no pain, and 10 indicative of "pain as bad as you can imagine". The score will be considered a continuous level of measurement.

    Time frame: Daily (Days 1-82)

  2. Self-Reported Opioid Use (Opioid Dose)

    To measure the change in opioid dose from baseline using the Opioid Sparing Diary Toolkit

    Time frame: Daily (Days 1-82)

  3. Self-Reported Opioid Use Frequency (Opioid Dose Frequency)

    To measure the change in opioid use frequency from baseline using the Opioid Sparing Diary Toolkit

    Time frame: Daily (Days 1-82)

Secondary outcomes

  1. Brief Pain Inventory (BPI)

    To evaluate and measure any changes in pain history, intensity, location, relief, and life interference indicators from baseline

    Time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)

  2. Hospital and Anxiety Depression Scale (HADS)

    To measure the change in depression and generalized anxiety from baseline. The HADS measures levels of anxiety and depression that a patient is experiencing. The HADS is a fourteen item scale. Seven of the items relate to a factor that measures anxiety and seven relate to a factor that measures depression. The seven items for each factor are summed into a total score and range from 0 to 21, with higher scores indicative of greater anxiety/depression. The scores will be analyzed as continuous level variables and one-sided paired-samples t-tests will be used to compare mean scores for anxiety and depression for all subjects between Week 1 (baseline) and Week 12 (EOS).

    Time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)

  3. Side Effect Checklist 29-item

    To evaluate the presence or absence of side effects associated with the intervention

    Time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)

  4. RAND Health Survey 36-item

    To measure the change in overall quality of life from baseline

    Time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)

  5. MOS Sleep Scale

    To measure the change in quality of sleep from baseline. The MOS Sleep Scale Self Report includes 12 items which measure 7 individual continuous-level factors relating to sleep quality: (a) sleep disturbances, (b) snoring, (c) sleep short of breath or headache, (d) sleep adequacy, (e) sleep somnolence, (f) sleep problems index I, and (g) sleep problems index II. Each of the seven factors is scored via a two-step process such that higher resulting scores are indicative of greater sleep problems. All 7 scores are measured at the continuous level.

    Time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)

  6. Treatment Satisfaction Questionnaire for Medication (TSQM)

    To measure the change in satisfaction with medication from baseline

    Time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)

  7. Bowel Function Inventory-Revised (BFI-R)

    To measure the change in Opioid-Induced Constipation from baseline

    Time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)

  8. Current Opioid Misuse Measure (COMM)

    To measure the change in Possible Opioid Misuse from baseline

    Time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)

  9. Numerical Opioid Side Effect (NOSE) Assessment

    To measure the change in Opioid Side Effect Severity from baseline

    Time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)

  10. OSD: Mood Scale Self Report (0-10)

    To measure the change in Mood from baseline. The Mood Scale is a 10 item Likert-scaled instrument with each of the 10 items scored from 1 = absolutely miserable to 10 = absolutely happy. The scores for each of the 10 items will be summed into a mood total score. The mood total score can range from 10 to 100, with higher scores indicative of happier states. The mood total score is a continuous level of measurement.

    Time frame: Daily (Days 1-82)

  11. OSD: Sleep Scale Self Report (0-10)

    To measure the change in Quality of Sleep from baseline. The Sleep Scale is a 10 item Likert-scaled instrument with each of the 10 items scored from 1 = worst imaginable to 10 = best . The scores for each of the 10 items will be summed into a sleep total score. The sleep total score can range from 10 to 100, with higher scores indicative of better quality sleep. The sleep total score is a continuous level of measurement.

    Time frame: Daily (Days 1-82)

  12. OSD: Bowel Movement 24-Hour Self Report Survey

    To measure the change in number of Bowel Movements from baseline

    Time frame: Daily (Days 1-82)

  13. FITBIT: Sleep Tracker

    To measure the change in quantity and quality of sleep from baseline

    Time frame: Daily (Days 1-82)

  14. FITBIT: Distance Tracker

    To measure the change in average weekly distance traveled from baseline

    Time frame: Daily (Days 1-82)

  15. FITBIT: Caloric Expenditure Tracker

    To measure the change in average weekly calories expended from baseline

    Time frame: Daily (Days 1-82)

  16. Medical Billing Claims Data for each participant

    To evaluate the change in Health Care Expenditures Related To Chronic Pain from baseline (average monthly expenditures before study)

    Time frame: Study Visits 1 & 5 (Days 1 & 82)

07

Study locations

1 of 1 sites recruiting
  • Daisy Research, Inc.
    Scottsdale, Arizona 85255, United States
    Recruiting
    • KENDRIC B SPEAGLE, BA · Contactkendric@daisyrx.com · 480-355-9000
    • Kendric B Speagle, BA · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2018 (actual). Primary completion is estimated for Jun 2019, 6 months after the start.

Of 60 phase 2 interventional studies under Chronic Pain, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2018
First posted
Dec 6, 2018
StartActual
Dec 1, 2018
Primary completionEst.
Jun 1, 2019
CompletionEst.
Jul 1, 2019
Last update
Dec 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03766269
Lead sponsor
Daisy Pharma Opioid Venture, LLC
Responsible party
Sponsor
First posted
Dec 6, 2018
Start date
Dec 1, 2018
Primary completion
Jun 1, 2019 (estimated)
Completion
Jul 1, 2019 (estimated)
Last update
Dec 6, 2018

Study contacts

Kendric B Speagle, BA
Contact
kendric@daisyrx.com
4803559000
Kendric B Speagle, BA
principal investigator · Daisy Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion